Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver.
OBJECTIVE
The purpose of this article is to review the use of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (gadoxetate disodium [Gd-EOB-DTPA]) in the cirrhotic liver and illustrate the imaging appearance of lesions commonly encountered in the cirrhotic liver.


CONCLUSIONS
Gd-EOB-DTPA shows promise as a problem-solving tool in the cirrhotic liver because it provides additional information that may be helpful in lesion detection and characterization. Further research is needed to optimize Gd-EOB-DTPA imaging protocols in cirrhosis and develop diagnostic criteria for liver lesions in the cirrhotic liver.
Cruite
Irene
I
Department of Radiology, University of California, San Diego, 92103, USA.
Schroeder
Michael
M
Merkle
Elmar M
EM
Sirlin
Claude B
CB
D002985:Clinical Protocols / Q000592:standards*; D003287:Contrast Media / Q000493:pharmacokinetics / Q000494:pharmacology*; D019786:Gadolinium DTPA / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging / Q000379:methods*
D003287:Contrast Media; C073590:gadolinium ethoxybenzyl DTPA; D019786:Gadolinium DTPA